Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug-Resistant Cancer Cells


  • This research was supported in part by Charles & Johanna Busch Biomedical and CA100098, CA111766 NIH grants. A.M.C. acknowledges Merck & Co., Inc. for support.


original image

Co-delivery of Doxorubicin and siRNAs by mesoporous silica nanoparticles into multidrug-resistance cancer cells with minimal premature release significantly enhances the efficacy of chemotherapy by conquering the nonpump resistance and possibly bypassing the efflux pump resistance (see image).